Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies

Elisabet E. Manasanch; David Berrios; Eric Fountain; Catherine M. Claussen; Tammy Chuang; Gregory Kaufman; Behrang Amini; Qaiser Bashir; Yago Nieto; Muzaffar Qazilbash; Krina Patel; Sheeba K. Thomas; Donna M. Weber; Zuzana Berkova; Gokce Toruner; Pei Lin; Lei Feng; Hans C. Lee; Robert Z. Orlowski; Chutima Kunacheewa

doi:10.1111/bjh.17344

Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies

Elisabet E. Manasanch, David Berrios, Eric Fountain, Catherine M. Claussen, Tammy Chuang, Gregory Kaufman, Behrang Amini, Qaiser Bashir, Yago Nieto, Muzaffar Qazilbash, Krina Patel, Sheeba K. Thomas, Donna M. Weber, Zuzana Berkova, Gokce Toruner, Pei Lin, Lei Feng, Hans C. Lee, Robert Z. Orlowski, Chutima Kunacheewa

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	e115-e120
Journal	British Journal of Haematology
Volume	192
Issue number	4
DOIs	https://doi.org/10.1111/bjh.17344
State	Published - Feb 2021

Keywords

HR myeloma
gene expression profiling
multiple myeloma
novel therapy

ASJC Scopus subject areas

Hematology

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1111/bjh.17344

Cite this

Manasanch, E. E., Berrios, D., Fountain, E., Claussen, C. M., Chuang, T., Kaufman, G., Amini, B., Bashir, Q., Nieto, Y., Qazilbash, M., Patel, K., Thomas, S. K., Weber, D. M., Berkova, Z., Toruner, G., Lin, P., Feng, L., Lee, H. C., Orlowski, R. Z., & Kunacheewa, C. (2021). Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. British Journal of Haematology, 192(4), e115-e120. https://doi.org/10.1111/bjh.17344

Manasanch, EE, Berrios, D, Fountain, E, Claussen, CM, Chuang, T, Kaufman, G, Amini, B , Bashir, Q , Nieto, Y , Qazilbash, M , Patel, K , Thomas, SK , Weber, DM, Berkova, Z, Toruner, G , Lin, P , Feng, L , Lee, HC , Orlowski, RZ & Kunacheewa, C 2021, 'Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies', British Journal of Haematology, vol. 192, no. 4, pp. e115-e120. https://doi.org/10.1111/bjh.17344

@article{459e3131b61d4eb6b2bf5df395b25fed,

title = "Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies",

keywords = "HR myeloma, gene expression profiling, multiple myeloma, novel therapy",

author = "Manasanch, {Elisabet E.} and David Berrios and Eric Fountain and Claussen, {Catherine M.} and Tammy Chuang and Gregory Kaufman and Behrang Amini and Qaiser Bashir and Yago Nieto and Muzaffar Qazilbash and Krina Patel and Thomas, {Sheeba K.} and Weber, {Donna M.} and Zuzana Berkova and Gokce Toruner and Pei Lin and Lei Feng and Lee, {Hans C.} and Orlowski, {Robert Z.} and Chutima Kunacheewa",

note = "Funding Information: This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672), the Leukemia and Lymphoma Society Specialized Center of Research (LLS SCOR), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Multiple Myeloma Research Foundation, the Chapman‐Perelman Foundation, and the University of Texas MD Anderson Moon Shot Program. RZO, the Florence Maude Thomas Cancer Research Professor, would like to acknowledge support from the National Cancer Institute (R01s CA184464 and 194264, and U10 CA032102), the Leukemia &Lymphoma Society (SCOR‐12206‐17), the Adelson Medical Research Foundation, the Brock Family Myeloma Research Fund, and the Jean Clarke HR Myeloma Research Fund. We thank participating patients and their families. Funding Information: EM has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, Merck; consultant fees from Takeda, Celgene, Sanofi, GSK and Adaptive Biotechnologies. HL has received consulting fees from Adaptive Biotechnologies, Celgene, Pimera and Takeda and research support from Amgen, Daiichi Sankyo, Janssen and Takeda. ST has received consulting fees from Amgen and research support from Acerta Pharma, Amgen, Array BioPharma, Bristol‐Myers‐Squibb, Celgene and Idera. RO has received consulting fees from Amgen, Bristol‐Myers‐Squibb, Celgene, GSK Biologicals, Ionis Pharmaceuticals, Janssen, Juno Therapeutics, Kite Pharma, Legend Biotech, Molecular Partners, Sanofi, Servier, and Takeda and research support from BioTheryX. EF, CC, TC, KP, GK, BA, SS, QB, YN, MQ, DW, GT, LF and CK report no conflicts of interest. ",

year = "2021",

month = feb,

doi = "10.1111/bjh.17344",

language = "English (US)",

volume = "192",

pages = "e115--e120",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies

AU - Manasanch, Elisabet E.

AU - Berrios, David

AU - Fountain, Eric

AU - Claussen, Catherine M.

AU - Chuang, Tammy

AU - Kaufman, Gregory

AU - Amini, Behrang

AU - Bashir, Qaiser

AU - Nieto, Yago

AU - Qazilbash, Muzaffar

AU - Patel, Krina

AU - Thomas, Sheeba K.

AU - Weber, Donna M.

AU - Berkova, Zuzana

AU - Toruner, Gokce

AU - Lin, Pei

AU - Feng, Lei

AU - Lee, Hans C.

AU - Orlowski, Robert Z.

AU - Kunacheewa, Chutima

N1 - Funding Information: This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672), the Leukemia and Lymphoma Society Specialized Center of Research (LLS SCOR), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Multiple Myeloma Research Foundation, the Chapman‐Perelman Foundation, and the University of Texas MD Anderson Moon Shot Program. RZO, the Florence Maude Thomas Cancer Research Professor, would like to acknowledge support from the National Cancer Institute (R01s CA184464 and 194264, and U10 CA032102), the Leukemia &Lymphoma Society (SCOR‐12206‐17), the Adelson Medical Research Foundation, the Brock Family Myeloma Research Fund, and the Jean Clarke HR Myeloma Research Fund. We thank participating patients and their families. Funding Information: EM has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, Merck; consultant fees from Takeda, Celgene, Sanofi, GSK and Adaptive Biotechnologies. HL has received consulting fees from Adaptive Biotechnologies, Celgene, Pimera and Takeda and research support from Amgen, Daiichi Sankyo, Janssen and Takeda. ST has received consulting fees from Amgen and research support from Acerta Pharma, Amgen, Array BioPharma, Bristol‐Myers‐Squibb, Celgene and Idera. RO has received consulting fees from Amgen, Bristol‐Myers‐Squibb, Celgene, GSK Biologicals, Ionis Pharmaceuticals, Janssen, Juno Therapeutics, Kite Pharma, Legend Biotech, Molecular Partners, Sanofi, Servier, and Takeda and research support from BioTheryX. EF, CC, TC, KP, GK, BA, SS, QB, YN, MQ, DW, GT, LF and CK report no conflicts of interest.

PY - 2021/2

Y1 - 2021/2

KW - HR myeloma

KW - gene expression profiling

KW - multiple myeloma

KW - novel therapy

UR - http://www.scopus.com/inward/record.url?scp=85099856795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099856795&partnerID=8YFLogxK

U2 - 10.1111/bjh.17344

DO - 10.1111/bjh.17344

M3 - Letter

C2 - 33486754

AN - SCOPUS:85099856795

SN - 0007-1048

VL - 192

SP - e115-e120

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this